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Accumulation of DNA damage has been linked to the process of aging and to the onset of age-related dis-
eases including diabetes. Studies on progeroid syndromes have suggested that the DNA damage response
is involved in regulation of metabolic homeostasis. DNA damage could impair metabolic organ functions by
causing cell death or senescence. DNA damage also could induce tissue inflammation that disturbs the
homeostasis of systemicmetabolism. Various roles of molecules related to DNA repair in cellular metabolism
are being uncovered, and such molecules could also have an impact on systemic metabolism. This review
explores mechanisms by which the DNA damage response could contribute to metabolic dysfunction.Introduction
Accumulation of DNA damage has been implicated in the phe-
notypic manifestations of aging in rodents and humans. DNA
damage can be caused by various endogenous or exogenous
stresses, including oxidative stress, telomere erosion, onco-
genic mutations, genotoxic stress, and metabolic stress (Lo´-
pez-Otı´n et al., 2013) (Figure 1). p53 is a key player in the intrinsic
cellular responses to DNA damage, and activation of p53 leads
to cell-cycle arrest, apoptosis, and senescence (Stewart and
Weinberg, 2006). Cellular senescence is defined as a state of
irreversible growth arrest accompanied by changes of both cell
morphology and gene expression (Hayflick and Moorhead,
1961). Accumulation of senescent cells, particularly senescent
stem cells, could impair tissue regeneration and homeostasis,
leading to metabolic dysfunction. In addition, accumulation of
senescent cells in the tissues leads to chronic inflammation
mediated by various proinflammatory cytokines and chemo-
kines (Rodier et al., 2009). There is accumulating evidence that
chronic inflammation associated with senescence has a pivotal
role in the progression of age-related diseases such as diabetes,
cardiovascular disease, and cancer (Tchkonia et al., 2013).
The number of people with obesity has increased dramatically
in the modern world, and this has become a major healthcare
problem for many societies. Obesity is known to be involved in
the development of diabetes and atherosclerotic disease and
has also been reported to increase the mortality rate, particularly
deaths from cardiovascular disease (Van Gaal et al., 2006). Sys-
temic insulin resistance is one of the crucial underlyingmolecular
mechanisms that accelerates various disease states in individ-
uals with obesity. It is widely accepted that an inflammatory
response in visceral fat plays an important role in the develop-
ment of systemic insulin resistance associated with obesity
(Rajah et al., 2001). Excessive energy intake induces the hy-
pertrophy of adipocytes by increasing the influx of fatty acids
and promotes a proinflammatory phenotype in adipose tissue.
These changes upregulate the production of chemoattractants,
including the chemokine (C-C motif) ligand 2 (CCL2), which is
also known as monocyte chemoattractant protein-1 (MCP-1).Subsequent recruitment of inflammatory cells results in a vicious
cycle of adipose tissue inflammation that leads to impairment of
glucose and lipid metabolism (Hotamisligil, 2006; Hotamisligil
et al., 1993; Kanda et al., 2006; Weisberg et al., 2003; Xu et al.,
2003). Tumor necrosis factor-alpha (TNF-a) is the best-charac-
terized proinflammatory cytokine secreted by inflammatory
macrophages that contributes to the development of systemic
insulin resistance via activation of c-Jun N-terminal kinase
(JNK) and IkB kinase (IKK), which inhibit insulin signaling inmeta-
bolic organs by serine phosphorylation of insulin receptor sub-
strates (Hotamisligil, 2006) (Figure 2). It has been reported that
inhibition of TNF-a by administration of a neutralizing antibody
improves insulin sensitivity in rodents (Arau´jo et al., 2007; Borst
et al., 2004).
TheDNA repair systemhas evolved in eukaryotes to overcome
DNA damage, and it includes processes such as homologous
recombination (HR), nonhomologous end joining (NHEJ), base
excision repair (BER), and nucleotide excision repair (NER)
(Lombard et al., 2005). Double-strand DNA breaks are repaired
by HR or NHEJ, whereas single-strand breaks are repaired by
BER or NER. The efficiency of the DNA repair system appears
to decrease with advancing age, leading to accumulation of
DNA damage in tissues (Lombard et al., 2005). In mice and hu-
mans, mutations of genes related to the DNA repair machinery
result in phenotypic changes that share features with age-asso-
ciated pathological conditions, including metabolic and cardio-
vascular abnormalities, as well as being associated with an
increased incidence of malignancies and a shortened lifespan
(Hasty et al., 2003; Lombard et al., 2005). Recent studies have
shown that factors involved in DNA repair also regulate cellular
metabolism in response to DNA damage to avoid further
genomic instability (Berkers et al., 2013; Imai and Guarente,
2014; Jeong et al., 2013). Evidence has also been obtained
that suggests the cellular response to DNA damage is critically
involved in the processes leading to impairment of glucose
metabolism. This review focuses on the role of the DNA damage
response, particularly activation of p53, in obesity and diabetes,
and also explores the mechanisms that may be involved.Cell Metabolism 20, December 2, 2014 ª2014 Elsevier Inc. 967
Figure 1. Stresses that Provoke the DNA Damage Response
Figure 2. Signaling Molecules that Promote Insulin Resistance via
DNA Damage
DNA damage activates p53 that directly or indirectly inhibits insulin signaling
via JNK/IKK-mediated pathways. DNA damage also induces b cell failure that
impairs insulin secretion. Expression of glucose transporters and enzymes is
directly regulated by p53, and it also influences glucose homeostasis by
modulating key metabolic regulators such as PGC-1. ATM, PARP, and sirtuins
have dual roles in DNA repair and metabolic processes, linking both in a
coordinated fashion.
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Chronological Aging
Aging is defined as a progressive decline of physiological func-
tion, leading to an increase in vulnerability and eventually to
death. DNA damage and mutations accumulate with age, and
this has been suggested to contribute to aging phenotypes
and to the onset of age-associated diseases (Lombard et al.,
2005). DNA damage can cause cells to enter an irreversible state
of cell-cycle arrest known as cellular senescence. Although
cellular senescence was initially discovered through in vitro
studies (Hayflick and Moorhead, 1961), it was subsequently
observed in vivo, and it was found that the number of senescent
cells increases with advancing age (Dimri et al., 1995; Herbig
et al., 2006). Cellular senescence has been suggested to have
a potent anticancer effect, but evidence has emerged that links
cellular senescence to age-related pathology (Campisi, 2005;
Collado et al., 2007).
The p53/p21 and p16/Rb signaling pathways are known to be
involved in regulation of cellular senescence, and p53 protein is
the best-characterized transcriptional factor mediating the DNA
damage response that is involved in preserving genomic stability
and inhibiting tumorigenesis. However, p53 has recently been
shown to have undesirable effects on aging and age-associated
diseases (Vousden and Lane, 2007). p53-mediated trans-
criptional activity increases with age, suggesting a role of DNA
damage-induced p53 activation in the development of aging phe-
notypes. Initial studies demonstrated that mice with one trun-
cated p53 mutant allele and constitutive p53 activation develop
premature aging, as well as showing resistance to cancer (Tyner
et al., 2002) (Table 1). Likewise, mice with overexpression of a
naturally occurring truncated p53 isoform have a short lifespan
and display premature aging (Maier et al., 2004) (Table 1). Activa-
tion of p53 signaling is also found in aged vessels, failing hearts,
and the visceral fat of obese persons, and it reportedly contrib-968 Cell Metabolism 20, December 2, 2014 ª2014 Elsevier Inc.utes to negative remodeling in atherosclerosis, as well as to pro-
gression of heart failure and the onset of diabetes (Minamino and
Komuro, 2008; Minamino et al., 2009; Sano et al., 2007). Other
studies have demonstrated that normal regulation of p53 may in-
crease longevity in mice (Garcı´a-Cao et al., 2002; Matheu et al.,
2007) (Table 1), suggesting that abnormal chronic activation of
p53 confers protection against cancer at the expense of reducing
the lifespan. Expression of p16 is also known to increase with ag-
ing inmice and humans and has been found to contribute to aging
phenotypes in the regenerative organs of mice (Kim and Sharp-
less, 2006; Krishnamurthy et al., 2004).
Association of Inflammation with Cellular Senescence
Chronic low-grade sterile inflammation is associated with age-
related diseases, such as diabetes, cancer, and cardiovascular
disease, and has been postulated to have a central role in accel-
erating these disease processes (Hu et al., 2004; Pai et al., 2004;
Schetter et al., 2010; Spranger et al., 2003). Interestingly, proin-
flammatory cytokines are elevated in the vascular cells (Donato
et al., 2008) and serum (Seidler et al., 2010) of elderly persons
with no overt disease, suggesting that inflammation accompa-
nying the natural aging process may contribute to the onset of
age-related diseases. Cellular senescence provides a possible
link between inflammation and aging (Freund et al., 2010). An
important feature shared by several types of senescent cells is
persistent upregulation of inflammatory molecules, including cy-
tokines and adhesion molecules that recruit inflammatory cells
(Tchkonia et al., 2013). Proinflammatory phenotypic changes of
senescent cells may be triggered by the DNA damage response,
which leads to activation of NF-kB and increased production of
inflammatory cytokines (Freund et al., 2010; Liu et al., 2011; Rod-
ier et al., 2009). A number of reports have demonstrated that
senescence-associated inflammation acts as a two-edged
sword. It is involved in maintaining tissue homeostasis as well
as inhibiting malignancy, since proinflammatory signals emitted
by senescent cells may help to prevent the development of
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gene expression that havemalignant potential (Kang et al., 2011;
Lujambio et al., 2013). However, senescence-associated
chronic inflammation could also promote tumor progression by
disrupting tissue architecture and inducing cellular damage
(Campisi et al., 2011; Yoshimoto et al., 2013). In a similar way,
senescence-associated inflammation may be beneficial by con-
tributing to the clearance of damaged cells and limiting fibrosis
during tissue repair, but persistent inflammation may have a
detrimental effect on tissue homeostasis that promotes age-
related diseases including diabetes (Tchkonia et al., 2013).
Association of Oxidative DNA Damage and Telomere
Shortening with Diabetes
A high level of oxidative DNA damage associated with an in-
crease of reactive oxygen species is found in rodents and
humans with diabetes. An increased serum level of 8-hydroxy
20-deoxy-guanosine, a sensitive biomarker for oxidative DNA
damage, has been found in obesity and diabetes and has also
been reported to show a positive correlation with the body
mass index of diabetic subjects (Al-Aubaidy and Jelinek,
2011). Telomeres are repeating DNA sequences located at the
ends of chromosomes that have a critical role in maintaining
genomic integrity (Stewart and Weinberg, 2006). As a conse-
quence of semiconservative DNA replication, the extreme termi-
nals of chromosomes are not completely duplicated, resulting in
successive shortening of the telomeres with each cell division.
When the telomeres reach a critically short length, they become
dysfunctional and the p53-dependent DNA damage response is
activated. Telomeres are known to become shorter with ad-
vancing age in humans, and telomere shortening is thought to
provoke age-associated pathology (Armanios, 2013). Progres-
sive telomere shortening is associated with obesity and insulin
resistance (Gardner et al., 2005). Among subjects with type 2
diabetes, those with atherosclerotic plaques have greater short-
ening of telomere length compared to those without plaques
(Adaikalakoteswari et al., 2007). Since oxidative stress is known
to accelerate telomere shortening, it is conceivable that the dia-
betic state further exacerbates impaired glucose homeostasis
by promoting telomere dysfunction.
Telomerase is an enzyme that adds telomeres to the terminals
of chromosomes. Telomerase-deficient mice have a normal
phenotype in the first generation, presumably because mice
possess very long telomeres (Blasco et al., 1997; Lee et al.,
1998). However, their telomeres become shorter with successive
generations, and these mice then exhibit a shortened lifespan as
well as various types of age-related pathology, including a
reduced capacity to respond to stresses such as wound healing
and hematopoietic ablation (Rudolph et al., 1999) (Table 1).
When fed a high-calorie diet, these mice develop glucose intol-
erance and insulin resistance without enhancement of obesity
(Minamino et al., 2009) (Table 1). Telomere dysfunction promotes
senescence of adipocytes by activating p53-dependent
signaling, thus inducing chronic inflammation in adipose tissue
and systemic insulin resistance (Figure 2). Telomere dysfunction
is also associated with impaired mitochondrial biogenesis
and function, decreased gluconeogenesis, and an increase of
reactive oxygen species (Sahin et al., 2011). Mechanistically,
telomere dysfunction leads to p53 activation, thereby downregu-lating the expression of peroxisome proliferator-activated re-
ceptor-g coactivator (PGC)-1a and b, which are transcriptional
cofactors that modulate expression of various genes involved
in mitochondrial function and glucose metabolism (Sahin et al.,
2011) (Figure 2). Insulin secretion is impaired in mice with short
telomeres, leading to glucose intolerance despite their b cell
mass being normal (Guo et al., 2011) (Table 1). Impaired insulin
secretion seems to be multifactorial and may be mediated by b
cell-autonomous defects of mitochondrial function as well as
aberrant Ca2+ handling. Taken together, these reports suggest
that age-associated telomere shortening can lead to impairment
of glucose homeostasis by inducing tissue inflammation and dis-
turbing cellular metabolism, as well as by reducing tissue regen-
eration.
Role of p53 Activation in Metabolic Disorders
White adipose tissuewas initially thought to bemainly involved in
energy storage, but it is now also recognized to be an endocrine
organ that secretes various cytokines and chemokines, which
are called adipokines (Hotamisligil, 2006; Ouchi et al., 2011).
It has been shown that inflammation of adipose tissue, charac-
terized by infiltration of inflammatory cells and increased pro-
duction of inflammatory cytokines, induces systemic insulin
resistance and accelerates the processes underlying the devel-
opment of diabetes (Johnson and Olefsky, 2013). DNA damage
has been linked to adipose tissue inflammation and systemic in-
sulin resistance (Shimizu et al., 2012). A high-calorie diet pro-
motes hypertrophy of adipocytes by increasing the influx of fatty
acids, leading to overproduction of reactive oxygen species,
accumulation of DNA damage, and cellular senescence in adi-
pose tissue. Under such conditions, p53 in adipose tissue plays
a pivotal role in inducing inflammation and systemic insulin resis-
tance (Minamino et al., 2009) (Figure 2 and Table 1). In mice fed a
chow diet, overexpression of adipose tissue p53 also provokes
inflammation and impairs glucose metabolism. Semaphorins
and their receptors (plexins) were originally identified as mole-
cules involved in axon guidance (Luo et al., 1993; Tamagnone
et al., 1999), but have been shown to also contribute to develop-
ment of the cardiovascular system during embryogenesis (Gitler
et al., 2004; Torres-Va´zquez et al., 2004). Semaphorin 3E
(Sema3E) is one of the class 3 semaphorins, and its receptor is
plexinD1 (Christensen et al., 1998). It was recently reported
that Sema3E is upregulated in obese visceral fat via a p53-
dependent mechanism and acts as a chemoattractant for plex-
inD1-positive inflammatory macrophages, thus contributing to
adipose tissue inflammation and systemic metabolic dysfunc-
tion through production of inflammatory cytokines (Shimizu
et al., 2013). It has been demonstrated that the p53/p21 signaling
pathway is critically involved in adipocyte differentiation and hy-
pertrophy, which links it to obesity and insulin resistance (Inoue
et al., 2008). There is also evidence that pancreatic b cell senes-
cence contributes to the pathogenesis of diabetes (Tavana and
Zhu, 2011). One recent study demonstrated that elevation of
glucose metabolism by b cells causes DNA double-strand
breaks and activation of p53, leading to b cell failure in mice
with type 2 diabetes (Tornovsky-Babeay et al., 2014) (Figure 2).
Likewise, mice expressing a truncated isoform of p53 show hy-
poinsulinemia and glucose intolerance with increased p21
expression in islets (Hinault et al., 2011) (Table 1). In contrast toCell Metabolism 20, December 2, 2014 ª2014 Elsevier Inc. 969
Table 1. Mutant Mice that Exhibit or Are Protected against Aging Phenotypes with Metabolic Dysfunction
Molecules Mouse models Aging phenotypes Metabolic phenotypes References




ND Tyner et al., 2002
p53 (p44) p44 transgenic (p44:
short isoform of p53)
Accelerated, short lifespan,
tumor resistant
b cell failure, glucose
intolerance










Armata et al., 2010; Sluss et al.,
2004
p53 Trp53 transgenic Normal lifespan, tumor
resistant
Better glucose tolerance on a
normal diet
Franck et al., 2012; Garcı´a-





ND Matheu et al., 2007
p53 (adipocytes) Fabp4-Cre;
Trp53flox/flox
ND Improved insulin resistance on
a high-calorie diet






ND Improved insulin resistance on
a high-calorie diet
Yokoyama et al., 2014
Telomerase Tert/, Terc/ Accelerated (late generation) Insulin resistance, b cell failure,
glucose intolerance
Guo et al., 2010; Minamino
et al., 2009; Rudolph et al.,
1999; Sahin et al., 2011
Sirt1 Sirt1/ Embryonic lethal, genomic
instability
ND Wang et al., 2008
Sirt6 Sirt6/ Accelerated, premature death Hypoglycemic phenotype Mostoslavsky et al., 2006
Sirt6 Sirt6 transgenic Extended maximum lifespan Protection against age-
associated insulin resistance
and glucose intolerance
Kanfi et al., 2010, 2012
Parp1 Parp1/ ND Better glucose tolerance,
increased energy expenditure
Bai et al., 2011
Parp1 Human PARP1 knockin Accelerated, short median
lifespan
Glucose intolerance Mangerich et al., 2010
Wrn Wrn/ No phenotype of premature
aging
Insulin resistance and glucose
intolerance on a high-calorie
diet
Lombard et al., 2000; Moore
et al., 2008
Wrn Wrn/Terc/ Accelerated, short lifespan Glucose intolerance Chang et al., 2004
Bub1b Bub1bH/H
(H: hypomorphic allele)
Accelerated, short lifespan ND Baker et al., 2004
Bub1b Bub1b transgenic Extended maximum lifespan,
tumor resistant
ND Baker et al., 2013a
Ercc1 Ercc1/ Accelerated, premature death ND Niedernhofer et al., 2006
Ercc1 Fabp4-Cre; Ercc1flox/ ND Glucose intolerance Karakasilioti et al., 2013
Atm Atm/ Mild aging phenotype Impaired insulin secretion Miles et al., 2007
Atm Atm/Apoe/,
Atm+/Apoe/
ND Insulin resistance, glucose
intolerance, atherosclerosis
Schneider et al., 2006
ND, not determined.
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reported that defects in p53 Ser18 phosphorylation result in
glucose intolerance and insulin resistance (Armata et al., 2010;
Sluss et al., 2004), whereas an additional copy of normally re-
gulated p53 improves glucose tolerance (Franck et al., 2012)
(Table 1), suggesting that physiological p53 activity is required
to maintain metabolic homeostasis.
Recently, information on the metabolic role of p53 at a cellular
level has emerged with regard to regulation of tumor develop-
ment as well as normal cellular homeostasis (Berkers et al.,
2013; Vousden and Ryan, 2009). For example, p53 downregu-
lates the expression of glucose transporters and glycolytic en-
zymes (Kondoh et al., 2005; Schwartzenberg-Bar-Yoseph970 Cell Metabolism 20, December 2, 2014 ª2014 Elsevier Inc.et al., 2004), while it upregulates TP53-induced glycolysis and
apoptosis regulator (Bensaad et al., 2006), thereby inhibiting
glycolysis (which is the preferred metabolic pathway for tumor
cells). p53 could negatively regulate the insulin signaling
pathway by upregulating PTEN (Stambolic et al., 2001) (Figure 2).
Under mild stress, p53 drives oxidative phosphorylation and
helps to maintain mitochondrial integrity (Lebedeva et al.,
2009; Matoba et al., 2006). In contrast, severe stress causes
p53 to repress expression of the transcriptional cofactors
PGC-1a and PGC-1b that are critical regulators of mitochondrial
biogenesis (Sahin et al., 2011) (Figure 2). Moreover, p53 func-
tions as a negative regulator of lipid synthesis by activating fatty
acid oxidation and by inhibiting fatty acid synthesis (Goldstein
Cell Metabolism
Reviewand Rotter, 2012). These metabolic functions of p53 may be
related to regulation of systemic metabolic homeostasis, but
its precise role remains to be determined.
The TP53 gene has a common polymorphism at codon 72, re-
sulting in two variants (Arg and Pro) that differ with respect to
their efficiency for inducing apoptosis and inhibiting tumorigen-
esis. Genetic analysis has demonstrated that p53 polymorphism
(Arg72Pro) influences insulin resistance in patients with type 2
diabetes (Burgdorf et al., 2011). Interestingly, single-nucleotide
polymorphism of a noncoding region near CDKN2A and
CDKN2B shows a strong association with diabetes (Saxena
et al., 2007). Variations of genes involved in DNA damage and
repair such as CHEK2 have been implicated in the onset of
type 2 diabetes (North et al., 2010), further emphasizing the
crucial role of the DNA damage response in human glucose
metabolism.
Metabolic and Cardiovascular Effects of the DNA
Damage Response
Heart failure develops when myocardial injury reduces cardiac
pump function. There is evidence of a close link between heart
failure and diabetes, and clinical studies have shown that sys-
temic metabolic dysfunction is prevalent among patients with
cardiac dysfunction (Witteles and Fowler, 2008). In addition, sys-
temic insulin resistance has been shown to be a risk factor for the
development of heart failure (Ingelsson et al., 2005). Heart failure
has been reported to promote the accumulation of DNA damage
in visceral fat and cardiac tissue that provokes adipose tissue
inflammation and systemic insulin resistance (Shimizu et al.,
2012). Excessive lipolysis related to activation of the sympa-
thetic nervous system leads to an increase of oxidative stress
that promotes DNA damage and adipose tissue inflammation
via p53-dependent signaling. Interestingly, inhibition of adipose
tissue inflammation by deletion of p53 can suppress metabolic
abnormalities and improve cardiac dysfunction, indicating that
a vicious feedback loop may exist between the heart and fat tis-
sue. Another line of evidence has suggested a close relationship
between vascular function and diabetes (Yokoyama et al., 2014).
Endothelial expression of p53 is markedly upregulated when
mice are fed a high-calorie diet, presumably due to an increase
of DNA damage related to metabolic stress. Inhibition of endo-
thelial p53 activation leads to improvement of insulin resistance
and obesity, while upregulation of endothelial p53 precipitates
metabolic abnormalities by inhibiting glucose homeostasis in
skeletal muscle (Table 1). These findings raise the possibility
that inhibiting the DNA damage response in certain tissues could
be a therapeutic target for blocking the vicious cycle between
metabolic abnormalities and cardiovascular dysfunction.
Role of Sirtuins in Metabolic Regulation and DNA Repair
Silencing information regulator 2 (Sir2) was originally identified as
a transcriptional silencer of mating foci and then was found to
mediate calorie restriction-induced longevity in the budding
yeast Saccharomyces cerevisiae (Lin et al., 2000). A number of
Sir2-related proteins (collectively known as sirtuins) have been
identified in many species ranging from yeasts to mammals
(Longo and Kennedy, 2006). Sirtuins are NAD+-dependent en-
zymes that display a conserved role in age-related pathology
and longevity (Finkel et al., 2009; Longo and Kennedy, 2006).Mammalian sirtuins have seven isoforms, and each isoform
shows distinctive localization (Haigis and Guarente, 2006).
SIRT1 and SIRT2 are found in both the nucleus and the cyto-
plasm, while SIRT3, SIRT4, and SIRT5 are localized to the mito-
chondria. SIRT6 and SIRT7 show nuclear localization. Because
of being NAD+ dependent, it has been suggested that sirtuins
play a critical role in regulating energy metabolism (Haigis and
Guarente, 2006). It is now widely accepted that sirtuins are
important regulators of various metabolic pathways, including
those involved in gluconeogenesis, glycolysis, oxidative phos-
phorylation, and fatty acid oxidation (Schwer and Verdin, 2008).
SIRT1 has been studiedmost extensively and is known to have
a role in both gluconeogenesis and glycolysis by regulating
various key modulators, such as PGC-1a and forkhead tran-
scription factors (FOXO) (Brooks and Gu, 2009) (Figure 2).
SIRT1 also regulates lipid metabolism by modulating various
transcriptional factors, including peroxisome proliferator-acti-
vated receptor (PPAR)-a and sterol-response element-binding
protein (SREBP) 1c (Rodgers and Puigserver, 2007; Walker
et al., 2010). With regard to DNA metabolism, sirtuins have
been reported to be involved in the DNA repair system, regula-
tion of chromatin structure, and maintenance of telomere integ-
rity (Lombard et al., 2005; Palacios et al., 2010). A critical role of
SIRT1 in DNA repair is strongly suggested by the observation
that most Sirt1-deficient mice undergo embryonic death due to
impairment of the DNA damage response and chromosomal ab-
normalities (Wang et al., 2008) (Table 1). SIRT6 is another nuclear
sirtuin like SIRT1, and it has also been shown to have a role both
in DNA repair and cellular metabolism. Sirt6-deficient mice
develop fatal hypoglycemia due to enhanced glucose uptake
by muscle and brown adipose tissue with loss of subcutaneous
fat, indicating a crucial role of SIRT6 in glucose and lipid homeo-
stasis (Mostoslavsky et al., 2006) (Table 1). Sirt6 deficiency also
results in hypersensitivity to genotoxic stress and genomic insta-
bility, thereby leading to various abnormalities that overlap with
age-associated pathology in mice (Mostoslavsky et al., 2006).
In contrast, mice that overexpress Sirt6 are protected against
both dietary and age-associated metabolic abnormalities, and
also have a longer lifespan (Kanfi et al., 2010, 2012) (Table 1). It
has been reported that SIRT6 is involved in repair of double-
strand DNA breaks by stabilizing DNA-dependent protein kinase
at sites of NHEJ repair (McCord et al., 2009). SIRT6 is also known
to contribute to maintenance of telomere integrity (Michishita
et al., 2008) and activates poly-ADP ribose polymerase (PARP)
1, thereby enhancing the repair of double-strand breaks by
NHEJ and HR (Mao et al., 2011).
Although PARPs have long been considered to be DNA dam-
age repair enzymes, recent evidence has suggested that these
enzymes have an important role in metabolic regulation by influ-
encing mitochondrial function and oxidative metabolism (Krish-
nakumar and Kraus, 2010). PARP1 and PARP2 interact with a
large number of nuclear receptor transcriptional factors (such
as PPARg and FOXO) to regulate mitochondrial and lipid oxida-
tion genes (Bai et al., 2007; Sakamaki et al., 2009). PARP1 is
responsible for the majority of cellular PARP activity (Krishnaku-
mar and Kraus, 2010). Given that SIRT1 and PARP1 are both
NAD+ dependent, these enzymes compete for the NAD+ pool,
and PARP1 probably influences Sirt1 activity by reducing the
bioavailability of NAD+ (Imai and Guarente, 2014) (Figure 2). InCell Metabolism 20, December 2, 2014 ª2014 Elsevier Inc. 971
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along with a reduced fat mass and increased glucose clearance
due to increased activity of SIRT1 in skeletal muscle and brown
adipose tissue and are therefore protected against metabolic
disease (Bai et al., 2011) (Table 1). Consistent with these find-
ings, a gain-of-function mouse model with overexpression of
human PARP1 shows premature onset of age-associated pa-
thology, enhanced adiposity (Mangerich et al., 2010), and
glucose intolerance (Table 1), indicating an essential role of this
enzyme in metabolic regulation and age-related diseases.
Since sirtuins and PARP are involved in both DNA repair and
cellular metabolism, they could function as a convergence point
in the regulation of both processes. It has been shown that DNA
damage directly activates metabolic responses in a coordinated
fashion. SIRT4 is best known for its role in glutamine metabolism
(Haigis and Guarente, 2006). Recently, it was reported that
SIRT4 inhibits entry of glutamine into the TCA cycle under geno-
toxic stress, thus preventing dysregulated cell proliferation and
genomic instability (Jeong et al., 2013). PARP shows chronic
activation with aging, and this is thought to contribute to an
age-associated decline of NAD+ (Imai and Guarente, 2014).
NAD+ supplementation has a protective effect against age-
induced impairment of glucose metabolism (Yoshino et al.,
2011), which further suggests a pathological influence of DNA
damage on metabolic regulation.
Relationship between DNA Damage and Metabolic
Dysfunction in Progeroid Syndromes
Progeroid syndromes are heritable human disorders that cause
premature aging. All of the known progeroid syndromes involve
defects of the DNA repair and DNA damage responses, suggest-
ing that maintenance of genomic stability has a central role in the
aging process, although these syndromes only partially mimic
normal human aging (Martin, 2005). Among the various human
progeroid syndromes, Werner syndrome (WRN) and Hutchin-
son-Gilford progeria syndrome (HGPS) are two of the best-char-
acterized disorders that most closely reproduce the features of
normal aging. The mutation causing WRN has been identified
as affecting a member of the RecQ family of helicases (Yu
et al., 1996). WRN protein has helicase, exonuclease, and sin-
gle-stranded DNA annealing activities and is involved in DNA
recombination, replication, repair, and transcription, as well as
in maintaining the integrity of telomeres (Opresko et al., 2004).
WRN is characterized by short stature, early graying and hair
loss, increased susceptibility to relatively uncommon cancers
(such as sarcomas, lymphomas, thyroid neoplasms, malignant
melanoma, and meningioma), scleroderma-like skin changes,
type 2 diabetes, and atherosclerosis. Death usually occurs in
middle life due to myocardial infarction or stroke. HGPS is
referred to as ‘‘childhood progeria’’ to differentiate it from
WRN, which is referred to as ‘‘adult progeria.’’ Patients with
HGPS appear normal at birth, but soon show premature aging
that is characterized by alopecia, atherosclerosis, osteolysis,
scleroderma, hyperpigmentation, and systemic insulin resis-
tance (Hennekam, 2006). Their mean lifespan is around 13 years,
and the main causes of death are coronary artery disease and
stroke. The genetic basis of HGPS was discovered in 2003,
when it was found thatmost personswith this disease have a sin-
gle nucleotide substitution that leads to aberrant splicing of the972 Cell Metabolism 20, December 2, 2014 ª2014 Elsevier Inc.LMNA gene encoding A-type nuclear lamins (Eriksson et al.,
2003). Lamin A protein is synthesized as a precursor protein
(prelamin A), and the mutation creates an abnormal prelamin A
protein termed progerin. Enhancement of the DNA damage
response and resulting p53-dependent senescence have been
postulated to contribute to the pathogenesis of these progeroid
syndromes (Gordon et al., 2014; Lombard et al., 2005).
Since patients with WRN and HGPS share common age-
related features, including type 2 diabetes, it has been assumed
that DNA damage per se can lead to impaired glucose homeo-
stasis in the general population. WRN protein null mice develop
normally and do not exhibit premature aging (Lombard et al.,
2000) (Table 1). In contrast, WRN protein-deficient mice with
shorter telomeres like humans show a variety of changes similar
to those seen in WRN patients, including diabetes, graying and
loss of hair, osteoporosis, and cataracts (Chang et al., 2004)
(Table 1), suggesting that telomere shortening is a key element
in the pathology of WRN. When fed a high-calorie diet, Wrn
null mice also develop weight gain, insulin resistance, and im-
paired glucose tolerance (Moore et al., 2008) (Table 1). It seems
likely that enhancement of genomic instability by additional
stresses leads to exacerbation of metabolic dysfunction in pro-
geroid syndromes, although the precise mechanisms leading
to development of type 2 diabetes in patients with WRN and
HGPS have not been fully elucidated.
The BUB1B (also known as BUBR1) gene encodes a mitotic
regulator that ensures accurate segregation of chromosomes.
BUB1B mutations are known to cause mosaic variegated aneu-
ploidy syndrome, which is a rare condition characterized by a
short lifespan, increased incidence of cancer, and develop-
mental delay (Hanks et al., 2004). It has been reported that
Bub1b expression decreases with age in various murine tissues,
while sustained Bub1b overexpression protects against aneu-
ploidy and cancer, delays the onset of age-related dysfunction,
and extends the lifespan of mice (Baker et al., 2013a) (Table 1),
suggesting a potential role of Bub1b in chronological aging.
Mutant mice carrying Bub1b hypomorphic alleles develop
various phenotypic features of premature aging that include a
short lifespan, fat loss, sarcopenia, and cataracts (Table 1).
These mice show selective accumulation of p16-positive cells
in tissues that develop age-associated pathological changes,
including adipose tissue, skeletal muscle, and the eye (Baker
et al., 2004). The contribution of cellular senescence to aging in
this mouse model has been demonstrated through an elegant
transgenic system that involved elimination of p16-positive cells
by a drug-inducible caspase. The inducible deletion of p16-pos-
itive senescent cells delays age-related tissue changes in mice
with a Bub1b progeroid background (Baker et al., 2011), indi-
cating that removal of senescent cells can inhibit tissue dysfunc-
tion associated with aging. In contrast to other mouse models of
premature aging, loss of p53 or p21 has been shown to accel-
erate cellular senescence in the adipose tissue and skeletal mus-
cles of Bub1b progeroid mice (Baker et al., 2013b), suggesting
that the p53/p21 pathways regulate cellular senescence in a
context-dependent manner.
ERCC1-ERCC4 (also known as XPF) is a structure-specific
heterodimeric endonuclease required for NER as well as for
repair of DNA interstrand crosslinks. Mutations in both of its sub-
units have been found to cause segmental progeroid syndromes
Figure 3. Potential Mechanisms by which the DNA Damage
Response Contributes to Metabolic Dysfunction
Various stresses provoke the DNA damage response, leading to an increase of
inflammation, a decrease of regeneration, impairment of cellular metabolism,
and suppression of endocrine function. These changes can disturb systemic
metabolic homeostasis and contribute to the onset of diabetes.
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Ercc4 deficiency show a severe progeroid phenotype (McWhir
et al., 1993; Tian et al., 2004) (Table 1). It was recently reported
that DNA damage triggers adipose tissue inflammation in a pro-
geroid mousemodel of Ercc1 deficiency, resulting in fat loss and
insulin resistance (Table 1). Deletion of Ercc1 leads to persistent
DNA damage and increases the expression of proinflammatory
cytokines in adipocytes via histone modifications associated
with transcriptional activation and dissociation of nuclear recep-
tor corepressor complexes from the promoters of proinflamma-
tory cytokines (Karakasilioti et al., 2013). These findings clearly
indicate that DNA damage itself is sufficient to trigger inflam-
mation that leads to impaired glucose metabolism. Investigation
of Ercc1-deficient mice has also revealed a shift toward anabo-
lism and reduced signaling via the growth hormone/insulin-like
growth factor (IGF)-1 pathway (Niedernhofer et al., 2006). Since
similar changes occur in response to chronic genotoxic stress
and calorie restriction or with aging, it is assumed that DNA dam-
age induces a metabolic shift from growth to preservation of the
organism in order to minimize further damage. Consistent with
this hypothesis, genetic disruption of Sirt6 in mice increases
genomic instability and shortens the lifespan alongwith suppres-
sion of the IGF axis (Mostoslavsky et al., 2006; Schwer et al.,
2010). There is evidence that p53 may be one of the regulatorslinking the DNA damage response to the IGF axis (Maier et al.,
2004), but it remains unclear how the metabolic shift induced
by DNA damage contributes to age-related pathology such as
effects on glucose homeostasis and the lifespan in progeroid
syndromes and during the normal aging process.
Ataxia telangiectasia (A-T) is an autosomal recessive disease
caused by mutations of the ataxia telangiectasia mutated (ATM)
gene (Martin, 2005). ATM is a protein kinase that has a critical
role in the DNA damage response to double-stranded DNA
breaks (Lombard et al., 2005). When ATM is activated, it phos-
phorylates p53 at a site that regulates transcriptional activity.
Patients with A-T are characterized by growth retardation, an
increased incidence of cancer, and neuronal degeneration. They
also have an elevated risk of insulin resistance and type 2 diabetes
(Bar et al., 1978; Schalch et al., 1970). Against an Apoe null back-
ground, Atm deficiency in mice causes exacerbation of various
features ofmetabolic syndrome, including increased adiposity, in-
sulin resistance, hypertension, and atherosclerosis (Schneider
et al., 2006) (Table 1). ATM seems to play a protective role by
inhibiting JNK, a kinase involved in inflammation and insulin resis-
tance (Aguirre et al., 2000; Hirosumi et al., 2002) (Figure 2). In addi-
tion, it was reported that Atm deficiency does not affect fasting
glucose levels and insulin sensitivity, but significantly impairs
glucose tolerance related to delayed insulin secretion by pancre-
atic b cells (Miles et al., 2007) (Figure 2 and Table 1). Furthermore,
Atm activation is required for insulin-induced phosphorylation of
Akt and for glucose transport in mouse skeletal muscle (Ching
et al., 2013) (Figure 2). Interestingly, the effects of Atm deficiency
are also observed in the absence ofDNAdamage, suggesting that
it can mediate the response to metabolic stress via a mechanism
independent of the DNA damage response. Mammalian cells that
lack ATM are known to have high ROS levels and show hypersen-
sitivity to oxidative stress (Barzilai et al., 2002). ATM is the sensor
for reactive oxygen species in human fibroblasts (Guo et al.,
2010), and it has also been reported to mediate mitochondrial
ROS signaling and to extend the lifespan of yeast (Schroeder
et al., 2013). A more recent study demonstrated that ATM pro-
motes antioxidant defenses and the repair of double-strand
DNA breaks by activating the pentose phosphate pathway, which
represents a link between DNA repair processes and cellular
metabolism (Cosentino et al., 2011).
Conclusions
Accumulation of DNA damage can promote metabolic dysfunc-
tion in two ways, which are cell-autonomous and non-cell-auton-
omousmechanisms (Figure 3). Tissue regeneration is impaired by
DNA damage-induced senescence and/or apoptosis of stem
cells and somatic cells, leading to metabolic dysfunction such
as pancreatic b cell loss. DNA damage induces non-cell-auto-
nomous tissue inflammation through upregulation of cytokines
and chemokines, resulting in interference with systemic insulin
signaling. DNA damage can also affect systemic metabolic ho-
meostasis through influences on cellular metabolism and the
endocrine system. In particular, activation of the DNA damage
response in certain tissues could influence the function of vital
metabolic organs, thereby provoking systemic insulin resistance.
Thus, better understanding of the systemic DNA damage res-
ponse may help us to develop novel therapeutic strategies for
metabolic disorders.Cell Metabolism 20, December 2, 2014 ª2014 Elsevier Inc. 973
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ReviewCells have evolved various systems to actively regulate
nutrient availability in order to maintain homeostasis, and have
also developed active DNA repair machinery to avoid detri-
mental genomic instability. Evidence has been obtained that
suggests that these two distinct cellular activities are highly co-
ordinated. In this review, we have described some of the key reg-
ulatory molecules with dual roles in regulating DNA repair and
cellular metabolism, including p53, sirtuins, PARP, and ATM.
Future studies are expected to identify additional factors that
modulate both processes and shed further light on the role of
DNA damage in metabolic homeostasis.
Another intriguing aspect of DNA damage is that cellular re-
sponses are determined by the extent of the damage. For
example, mild DNA damage induces reversible cell-cycle arrest
to allow repair, whereas moderate to severe DNA damage leads
to senescence or death that prevents the accumulation of
potentially tumorigenic damaged cells. However, an exces-
sively prolonged DNA damage response has a detrimental
impact on metabolic homeostasis as well as on tumorigenesis
via cell-autonomous and/or non-cell-autonomousmechanisms.
Likewise, normal p53 activity is required for the physiological
regulation of glucose metabolism, but inhibiting dysregulated
p53 activation is beneficial for attenuating insulin resistance
associated with dietary obesity, suggesting that fine-tuning of
the DNA damage response is critical for the prevention and
treatment of metabolic diseases.
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